As a result, Kim championed what he called super remarketing in which brands combine remarketing of
high engagement
content with demographic, interest and
behavioral targeting.
PsychoGenics has pioneered the translation of rodent
behavioral responses into robust,
high throughput,
high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.